- Home
- BGLC vs VIRX Comparison
BGLC vs VIRX Comparison
Compare BGLC & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- VIRX
- Stock Information
- Founded
- BGLC 2017
- VIRX 2007
- Country
- BGLC Malaysia
- VIRX United States
- Employees
- BGLC N/A
- VIRX N/A
- Industry
- BGLC Medical Specialities
- VIRX Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- VIRX Health Care
- Exchange
- BGLC Nasdaq
- VIRX Nasdaq
- Market Cap
- BGLC 7.6M
- VIRX 7.7M
- IPO Year
- BGLC N/A
- VIRX N/A
- Fundamental
- Price
- BGLC $0.30
- VIRX $0.15
- Analyst Decision
- BGLC
- VIRX Buy
- Analyst Count
- BGLC 0
- VIRX 4
- Target Price
- BGLC N/A
- VIRX $5.00
- AVG Volume (30 Days)
- BGLC 78.2K
- VIRX 2.7M
- Earning Date
- BGLC 11-20-2024
- VIRX 11-13-2024
- Dividend Yield
- BGLC N/A
- VIRX N/A
- EPS Growth
- BGLC N/A
- VIRX N/A
- EPS
- BGLC N/A
- VIRX N/A
- Revenue
- BGLC $9,183,168.00
- VIRX N/A
- Revenue This Year
- BGLC N/A
- VIRX N/A
- Revenue Next Year
- BGLC N/A
- VIRX N/A
- P/E Ratio
- BGLC N/A
- VIRX N/A
- Revenue Growth
- BGLC N/A
- VIRX N/A
- 52 Week Low
- BGLC $0.31
- VIRX $0.15
- 52 Week High
- BGLC $3.39
- VIRX $1.31
- Technical
- Relative Strength Index (RSI)
- BGLC 28.91
- VIRX 21.60
- Support Level
- BGLC $0.32
- VIRX $0.17
- Resistance Level
- BGLC $0.38
- VIRX $0.21
- Average True Range (ATR)
- BGLC 0.02
- VIRX 0.02
- MACD
- BGLC -0.00
- VIRX -0.00
- Stochastic Oscillator
- BGLC 0.00
- VIRX 0.00
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
About VIRX Viracta Therapeutics Inc.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.